PTO/SB/03a (01-10)
Approved for use through 97/31/2012 OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
and to a collection of information unless it contrains a valid OMB control number;

NFORMATION DISCLOSURE STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	Application Number		10606284		
	Filing Date		2003-06-25		
	First Named Inventor SEPP		PPINEN		
	Art Unit		2618		
	Examiner Name	EUGE	ENE YUN		
	Attorney Docket Number		944-003.151-1		

	U.S.PATENTS					Remove					
Examiner Initial*	Cite No	Patent Number	Kind Issue Date Name of Patentee or Applicant Releval			s,Columns,Lines where ant Passages or Relevant as Appear					
	1										
If you wis	h to ad	d additional U.S. Pate	nt citatio	n inform	ation pl	lease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite N	Publication Number	Kind Code ¹	Publication Name of Patentee of Applicant Delevent D			Columns,Lines where nt Passages or Relevant Appear				
	1										
If you wisl	If you wish to add additional U.S. Published Application citation information please click the Add button. Add										
				FOREIG	SN PA1	ENT DOCUM	ENTS		Remove		
Examiner Initial*		Foreign Document Number ³	Country Code ²	buntry Kind Publication Applicant of cited Applicant of cited			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		т.		
	1										
If you wish to add additional Foreign Patent Document citation information please click the Add button Add											
NON-PATENT LITERATURE DOCUMENTS Remove											
Examiner Initials*	Examiner Cite Initiats* Vince (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s). Tsublisher, city, and/or country where publisher.						Тs				

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10606284	
	Filing Date		2003-06-25	
	First Named Inventor	SEPP	INEN	
	Art Unit		2618	
	Examiner Name	EUGE	ENE YUN	
	Attorney Docket Numb	er	944-003.151-1	

1 Korean Office Action marked November 30, 2010 in parallel Korean Patent Application No. 10-2004 and English translation of same (3 pages)	020918 (3 pages)
---	------------------

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature Date Considered Date Considered

Date Considered

FixAMINER: Initial if reference consistend, whether or not clastion is in conformance with MPEP 606. Draw line through a citation if not in conformance and not considered, include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at inver_USPTO_GOV or MPEP 9910A. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the religion of the Emperor must precede the serial number of the patent document. ³ Wind of document to the separate serial bodourset under the Vision Standard ST.4 (see Standard ST.4) is to be called the comment under the Vision Standard ST.4 (see Standard ST.4) is subject. ³ Applicated to is obtained a CREAT to the Standard ST.4 (see Standard ST.4) is subject. ³ Applicated to is obtained a CREAT to Standard ST.4 (see Standard ST.4) is subject to the Vision ST.4 (see Standard ST.4) is subject to the Vis

English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10606284			
Filing Date		2003-06-25			
First Named Inventor	SEPPINEN				
Art Unit		2618			
Examiner Name	EUGE	UGENE YUN			
Attorney Docket Numb	er	944-003 151-1			

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(appropriate selection(s):
--	---------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(s).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- □ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

of the agricult.							
Signature	/Francis J. Maguire/	Date (YYYY-MM-DD)	2010-12-15				
Name/Print	Francis J. Maguire	Registration Number	31.391				

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) and application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfiling. U.S. Operatment of Commence, P. 0. Box 1450, Alexandrin, V.S. 2313-1450. DING SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandrin, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the stackhold from reliable to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. (2)(2)(2) familishing of the information solicided is columbra; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested requirement of the patient of the pati

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the sublect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, ourspant to 5 U.S.C. S52a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, during an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application presume to 58 U.S. C. 12(p) or issuance of a patent pursuant to 58 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 11, 4s as routine use, to the public fifthe record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by whiter a published application, an application open to public inscredience or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.